Verona Pharma price target raised to $93 from $74 at Wells Fargo

Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $93 from $74 and keeps an Overweight rating on the shares. Consistent with the firm’s longitudinal channel checks, Ohtuvayre’s launch continues to build momentum with more prescriptions in the first two months of Q1 2025 than in Q4 2024, marking another quarter in which Ohtuvayre is tracking well above comparable sales/Street.